Nephros Signs Exclusive License and Supply Agreement With Medica
Nephros Inc. has signed an exclusive license and supply agreement with Medica S.p.A. for marketing and selling filtration products using Medica's Medisulfone ultrafiltration technology. The agreement includes minimum purchase commitments by Nephros, starting at €4,976,000 in 2026 and increasing to €6,300,000 by 2030. It replaces a previous agreement and extends through December 31, 2030.
Nephros Inc. announced that it has entered into a new license and supply agreement with Medica S.p.A., an Italy-based medical product manufacturer, for the marketing and sale of filtration products based on Medica’s proprietary Medisulfone ultrafiltration technology. The agreement grants Nephros exclusive rights to market, promote, distribute, offer for sale, and sell the products in the defined territory, and includes minimum annual aggregate purchase commitments by Nephros totaling €4,976,000 in 2026, increasing to €6,300,000 in 2030. The new agreement supersedes and replaces a prior agreement dated December 11, 2023, which was terminated upon entry into the new arrangement. The term of the agreement extends through December 31, 2030, unless earlier terminated under specified conditions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nephros Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-025155), on November 26, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
